Mylan Confirms First-to-File Patent Challenge for CANASA
July 11, 2013 at 07:31 AM EDT
Mylan Inc. (Nasdaq: MYL ) today confirmed that the company has been sued by Aptalis in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Mesalamine Rectal Suppositories, 1000 mg. This product is the generic version of CANASA®. Mylan filed a substantially complete
